US Cancer Vaccine Market Explored in New RNCOS E-Services Pvt. Ltd. Report Published at MarketPublishers.com

London, UK (PRWEB) September 20, 2012

Cancer treatment remains the burning issue even in the 21st century despite the discovery of new treatment techniques and medicines. Much attention is paid to the prevention of the disease. A large number of medical laboratories around the globe struggle to create the universal vaccine able to protect men from all cancer types.

Approximately 50 percent share in the cancer vaccines market belongs to the USA. Major companies engaged in this business are based or have offices in the country. They are set to maintain their position in the coming years due to highly successful results of their research activity.

New market research report US Cancer Vaccine Market Analysis elaborated by RNCOS E-Services Pvt. Ltd. provides a comprehensive guide to the US cancer vaccine market analysis. It offers a full coverage of the key market restraints and challenges, examines current market size and its major participants. Cancer statistics by demographics, valuable insight on key products available, the pipeline cancer vaccines, vaccine approval process and future outlook can be found in the study.

The companies covered in the research: Merck & Co., GSK, Dendreon, Bavarian Nordic, Celldex Therapeutics, Kael-GemVax, Oxford BioMedica, Galena Biopharma.

Report Details:

Title: US Cancer Vaccine Market Analysis

Published: September, 2012

Pages: 135

Price: US$ 1,200.00

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/us-cancer-vaccine-market-analysis.html

Report Contents:

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. CANCER STATISTICS BY DEMOGRAPHICS

3.1 Prevalence, Incidences and Mortality (2008-2016)

3.2 Leading States by Incidence

3.3 Leading Cancers by Incidence

3.3.1 Male Cancer Incidences

3.3.2 Female Cancer Incidences

3.3.3 Age-Group

4. CANCER VACCINES MARKET OUTLOOK

4.1 Market Analysis and Segmentation

4.2 Key Product Analysis

4.2.1 Provenge

Leave a Reply